Ashkon Software







 

ACXP - Acurx Pharmaceuticals, Inc.


ACXP Stock Chart

ACXP Profile

Acurx Pharmaceuticals, Inc. logo

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.

ACXP Revenue Chart

ACXP Earnings


 

Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer